CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 148 enrolled
Drug / intervention
Progesterone +1 moredrug
Likely dose
Progesterone 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03729869
NCT03729869Phase 2Completed
CompareCT.gov

Impact of Progesterone on Stress Reactivity and Cannabis Use

Medical University of South Carolina·interventional·Posted Nov 5, 2018·Updated Sep 28, 2023

In Brief

A Phase 2 clinical trial evaluating Progesterone and Placebo for Cannabis Use. Completed, enrolled 148 participants across 1 site.

Detailed Summary

This is a research study to find out if a hormone called progesterone affects marijuana users' stress response and marijuana use. Progesterone is a naturally occurring sex hormone involved in the menstrual cycle and reproduction, and has been shown to reduce withdrawal symptoms when people stop using substances like cocaine and nicotine. It is not FDA approved for treating cannabis users and is considered an investigational drug in this study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCannabis Use
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedNov 5, 2018
Enrollment StartJan 18, 2019
Primary CompletionNov 9, 2022
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 7.7 years ago

Interventions

Progesteronedrug

200 mg of exogenous progesterone twice a day

Placebodrug

One dose of matched placebo twice a day.